| Patent application number | Description | Published |
|---|
| 20080199518 | Controlled-release formulation of piperazine-piperidine antagonists and agonists of the 5-HT1A receptor having enhanced intestinal dissolution - The present invention relates to controlled-release beads comprising diquinoline-substituted piperazine-piperidine compounds, such as 5-fluoro-8-{4-[4-[(6-methoxyquinolin-8-yl)piperazin-1-yl]piperidin-1-yl}quinoline, or pharmaceutically acceptable salts thereof; to multiple particulate formulations comprising such beads; to methods of preparing such beads; and to methods of treating 5-HT | 08-21-2008 |
| 20080234340 | Synthesis and characterization of polymorph form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-YL)thiazol-4-YL)benzonitrile - A polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile and methods of preparing Form II are described. Also provided are methods of contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, and hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake, and synchronizing estrus including using polymorph Form II of 4-(2-(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile. | 09-25-2008 |
| 20090176827 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF - The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family. | 07-09-2009 |
| 20100056520 | FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS - The present invention is directed to formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA | 03-04-2010 |
| 20100093725 | SEMI-SOLID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS - The present invention is directed to semi-solid formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA | 04-15-2010 |
| 20100113443 | LIQUID FORMULATIONS OF PHOSPHOLIPASE ENZYME INHIBITORS - The present invention relates to liquid formulations of inhibitors of phospholipase enzymes, such as cytosolic PLA | 05-06-2010 |
| 20100113541 | CRYSTAL FORMS OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL - The present invention is directed to monohydrate and anhydrate crystal forms of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol, an estrogenic receptor modulator useful in the treatment of, for example, diseases related to abnormal levels of estrogen. | 05-06-2010 |
| 20100216886 | POLYMORPHS OF N2-(1,1'-BIPHENYL-4-YLCARBONYL)-N1-[2-(4-FLUOROPHENYL)-1,1-DIMETHYLETHYL]- -L-ALPHA-GLUTAMINE - Disclosed are novel polymorphic forms of N | 08-26-2010 |
| 20100267715 | Polymorph Form II of Tanaproget - Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject. | 10-21-2010 |
| 20110166072 | Polypeptides Selective for avB3 Integrin, Including Pegylated Polypeptides, And Pharmaceutical Uses Thereof - The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective αvβ3 integrin antagonists for treatment and prevention of αvβ3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant | 07-07-2011 |
